Market Cap 939.44M
Revenue (ttm) 566.77M
Net Income (ttm) 48.16M
EPS (ttm) N/A
PE Ratio 5.24
Forward PE 4.94
Profit Margin 8.50%
Debt to Equity Ratio 2.69
Volume 291,900
Avg Vol 408,572
Day's Range N/A - N/A
Shares Out 32.25M
Stochastic %K 12%
Beta 0.82
Analysts Strong Sell
Price Target $42.80

Latest News on COLL

Collegium Reports Record Third Quarter 2024 Financial Results

Nov 7, 2024, 4:02 PM EST - 3 months ago

Collegium Reports Record Third Quarter 2024 Financial Results


Collegium Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 7 months ago

Collegium Reports Second Quarter 2024 Financial Results


Collegium Reports First Quarter 2024 Financial Results

May 9, 2024, 4:02 PM EDT - 10 months ago

Collegium Reports First Quarter 2024 Financial Results


Top 10 Small-Cap Stocks (SA Quant)

Mar 12, 2024, 5:00 AM EDT - 1 year ago

Top 10 Small-Cap Stocks (SA Quant)

ANIP APOG BASE BLBD GCT PLMR RAMP


Collegium to Participate in Upcoming Investor Conferences

Nov 8, 2023, 8:00 AM EST - 1 year ago

Collegium to Participate in Upcoming Investor Conferences


Collegium Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 4:01 PM EST - 1 year ago

Collegium Reports Third Quarter 2023 Financial Results


Collegium Pharmaceutical: Delivering On Promises

Oct 24, 2023, 2:59 PM EDT - 1 year ago

Collegium Pharmaceutical: Delivering On Promises


Collegium to Participate in Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 1 year ago

Collegium to Participate in Jefferies Healthcare Conference


Collegium Reports First Quarter 2023 Financial Results

May 4, 2023, 4:01 PM EDT - 1 year ago

Collegium Reports First Quarter 2023 Financial Results


Collegium Provides 2023 Financial Guidance

Jan 4, 2023, 8:00 AM EST - 2 years ago

Collegium Provides 2023 Financial Guidance


Appeals Court Affirms Validity of Collegium's Belbuca® Patents

Dec 22, 2022, 8:00 AM EST - 2 years ago

Appeals Court Affirms Validity of Collegium's Belbuca® Patents